Keywords: janssen-cilag, topiramate, expected, grow, migraine, prevention, market
Janssen-Cilag's topiramate expected to grow migraine prevention market
Article | 29 September 2003
Johnson and Johnson subsidiary Janssen-Cilag used the occasion of the International Headache Congress, held in Rome, Italy, September 13-16, to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
